Cargando…

Correction: Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8118240/ https://www.ncbi.nlm.nih.gov/pubmed/33984052 http://dx.doi.org/10.1371/journal.pone.0251897

Ejemplares similares

Angiotensin II receptor blocker or angiotensin-converting enzyme inhibitor use and COVID-19-related outcomes among US Veterans
por: Derington, Catherine G., et al.
Publicado: (2021)

The Fetal Safety of Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Moretti, Myla E., et al.
Publicado: (2012)

Pneumonia Risk and Use of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Liu, Chia-Lin, et al.
Publicado: (2013)

Effect of angiotensin converting enzyme inhibitor and angiotensin II receptor blocker on the patients with sepsis
por: Lee, Hyun Woo, et al.
Publicado: (2021)

Fracture Risk and Use of Angiotensin-Converting Enzyme Inhibitors or Angiotensin II Receptor Blockers
por: Holloway-Kew, Kara L., et al.
Publicado: (2022)

Angiotensin-Converting Enzyme Inhibitor and Angiotensin Receptor Blocker Use Associated with Reduced Mortality and Other Disease Outcomes in US Veterans with COVID-19
por: Rizk, John G., et al.
Publicado: (2021)

Angiotensin‐Converting Enzyme Inhibitors, Angiotensin II Receptor Blockers, and Outcomes in Patients Hospitalized for COVID‐19
por: Pan, Michael, et al.
Publicado: (2021)

Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Onset of Hyperkalemia following the Administration of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker
por: Jun, Hye-Ran, et al.
Publicado: (2021)

Differential Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers on COVID-19
por: Su, Lianjiu, et al.
Publicado: (2021)

Usage of Angiotensin-Converting Enzyme Inhibitor or Angiotensin II Receptor Blocker in Hypertension Intracerebral Hemorrhage
por: Zhang, Chao, et al.
Publicado: (2021)

Effect of angiotensin converting enzyme inhibitors and angiotensin receptor blockers on hemoglobin levels
por: Ajmal, Adnan, et al.
Publicado: (2013)

Association Between Angiotensin-Converting Enzyme Inhibitors, Angiotensin Receptor Blockers, and Suicide
por: Mamdani, Muhammad, et al.
Publicado: (2019)

Effects of angiotensin receptor blockers and angiotensin-converting enzyme inhibitors on COVID-19
por: Li, Xiao-Long, et al.
Publicado: (2021)

Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Gersh, Felice L.
Publicado: (2020)

Relating angiotensin‐converting enzyme inhibitors or angiotensin receptor blockers with incidence or mortality of COVID‐19
por: Wong, Martin C.S., et al.
Publicado: (2020)

Combination therapy of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers in chronic kidney disease
por: Vasavada, Nina, et al.
Publicado: (2009)

In reply—Angiotensin-Converting Enzyme 2 and the Resolution of Inflammation: In Support of Continuation of Prescribed Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers
por: Sanchis-Gomar, Fabian, et al.
Publicado: (2020)

Effect of Statins, Metformin, Angiotensin-Converting Enzyme Inhibitors, and Angiotensin II Receptor Blockers on Age-Related Macular Degeneration
por: Lee, Hyesung, et al.
Publicado: (2019)

Assessing the outcomes of prescribing angiotensin converting enzyme inhibitors and angiotensin receptor blockers for COVID-19 patients
por: Mekary, Wissam, et al.
Publicado: (2023)

Author Correction: Angiotensin-converting enzyme inhibitors or angiotensin receptor blocker monotherapy retard deterioration of renal function in Taiwanese chronic kidney disease population
por: Zheng, Cai-Mei, et al.
Publicado: (2020)

Effect of spironolactone combined with angiotensin-converting enzyme inhibitors and/or angiotensin II receptor blockers on chronic glomerular disease
por: WANG, WEISONG, et al.
Publicado: (2013)

Angiotensin Converting Enzyme Inhibitor and Angiotensin II Receptor Blocker Use Among Outpatients Diagnosed With COVID-19
por: Bae, David J., et al.
Publicado: (2020)

Angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers and hemorrhoids: A nationwide, population-based study
por: Hu, Wei-Syun, et al.
Publicado: (2023)

Over diagnosis of bradykinin angioedema in patients treated with angiotensin-converting enzyme inhibitors or angiotensin II receptor blockers()
por: Douillard, Marie, et al.
Publicado: (2023)

Adherence and optimization of angiotensin converting enzyme inhibitor/angiotensin II receptors blockers and beta‐blockers in patients hospitalized for acute heart failure
por: Carubelli, Valentina, et al.
Publicado: (2021)

Aliskiren – an alternative to angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in the therapy of arterial hypertension
por: Zaporowska-Stachowiak, Iwona, et al.
Publicado: (2013)

Cognitive enhancing effect of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on learning and memory
por: Nade, V. S., et al.
Publicado: (2015)

Is angiotensin-converting enzyme inhibitors/angiotensin receptor blockers therapy protective against prostate cancer?
por: Mao, Yeqing, et al.
Publicado: (2016)

The controversy of using angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in COVID-19 patients
por: Harky, Amer, et al.
Publicado: (2021)

Angiotensin receptor blockers, but not angiotensin-converting enzyme inhibitors, inhibit abnormal bone changes in spondyloarthritis
por: Choi, Jin Sun, et al.
Publicado: (2023)

Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal Studies
por: Kriszta, Gábor, et al.
Publicado: (2021)

Angiotensin converting enzyme inhibitors and angiotensin receptor blockers improved the outcome of patients with severe COVID-19 and hypertension
por: Meng, Xiao, et al.
Publicado: (2020)

Role of angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in cryoballoon ablation outcomes for paroxysmal atrial fibrillation
por: Al-Seykal, Ibragim, et al.
Publicado: (2022)

Comparison of clinical outcomes of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors in patients with acute myocardial infarction
por: Chen, Chih-Wei, et al.
Publicado: (2023)

Impact of Angiotensin I-converting Enzyme Inhibitors and Angiotensin II Type-1 Receptor Blockers on Survival of Patients with NSCLC
por: Miao, Lili, et al.
Publicado: (2016)

Impact of Angiotensin-Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers in Hypertensive Patients with COVID-19 (COVIDECA Study)
por: Mustafic, Hazrije, et al.
Publicado: (2021)

Immunomodulatory Activity of the Most Commonly Used Antihypertensive Drugs—Angiotensin Converting Enzyme Inhibitors and Angiotensin II Receptor Blockers
por: Bryniarski, Paweł, et al.
Publicado: (2022)

Effect of angiotensin converting enzyme inhibitors and angiotensin II receptor blockers on need for operative intervention for idiopathic adhesive capsulitis
por: Bi, Andrew S., et al.
Publicado: (2023)

Premorbid Use of Beta-Blockers or Angiotensin-Converting Enzyme Inhibitors/Angiotensin Receptor Blockers in Patients with Acute Ischemic Stroke
por: Zeng, Yuanyuan, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_301t39dkse6lhrgviu8eqqnn0k